Latest News and Press Releases

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced...

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Dublin, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering. Thought Leader...

Vertero unveils new strategic direction, promising lead asset targeting peripheral drivers of Parkinson’s disease, and Series D financing.

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Sleep Service Providers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application,...

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)

Paris, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 –...

Réduction de plus de 88 % des épisodes d'incontinence urinaire dans la cohorte à faible dose après 12 semaines.Bonne tolérance, sans effet indésirable systémiquePremier médicament à ADN ciblant...

Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeksGood tolerability with no systemic side effectsFirst DNA medicine to selectively target, at the local...

Neura Health Secures $11.4M Series A led by American Heart Association's Go Red for Women Venture Fund to expand tech-enabled neurology care model.